A Single Arm, Open Lable, Dose Escalation Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy of KN026 Monotherapy in Patients With HER2-positive Advanced Malignant Breast and Gastric Cancer
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs KN-026 (Primary)
- Indications Advanced breast cancer; Gastric cancer
- Focus Adverse reactions; First in man
- Sponsors Alphamab Oncology
- 01 Nov 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Jun 2020.
- 06 Jun 2019 Results published in the Alphamab Oncology Media Release
- 28 Sep 2018 Status changed from not yet recruiting to recruiting.